top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Thomas J. Schall net worth and biography

Thomas Schall Biography and Net Worth

CEO of ChemoCentryx

Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

What is Thomas J. Schall's net worth?: The estimated net worth of Thomas J. Schall is at least $124.43 million as of August 4th, 2022. Dr. Schall owns 2,393,352 shares of ChemoCentryx stock worth more than $124,430,370 as of April 24th. This net worth approximation does not reflect any other assets that Dr. Schall may own. Additionally, Dr. Schall receives an annual salary of $1,210,000.00 as CEO at ChemoCentryx. Learn More about Thomas J. Schall's net worth.
How old is Thomas J. Schall?: Dr. Schall is currently 63 years old. There are 5 older executives and no younger executives at ChemoCentryx. Learn More on Thomas J. Schall's age.
What is Thomas J. Schall's salary?: As the CEO of ChemoCentryx, Inc., Dr. Schall earns $1,210,000.00 per year. Learn More on Thomas J. Schall's salary.
How do I contact Thomas J. Schall?: The corporate mailing address for Dr. Schall and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected]. Learn More on Thomas J. Schall's contact information.
Has Thomas J. Schall been buying or selling shares of ChemoCentryx?: Thomas J. Schall has not been actively trading shares of ChemoCentryx during the past quarter. Most recently, Thomas J. Schall sold 130,000 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.24, for a transaction totalling $6,531,200.00. Following the completion of the sale, the chief executive officer now directly owns 2,393,352 shares of the company's stock, valued at $120,242,004.48. Learn More on Thomas J. Schall's trading history.
Who are ChemoCentryx's active insiders?: ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Thomas J. Schall Insider Trading History at ChemoCentryx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/4/2022	Sell	130,000	$50.24	$6,531,200.00	2,393,352
12/15/2020	Sell	17,619	$65.01	$1,145,411.19	2,279,710
6/15/2020	Sell	90,753	$65.08	$5,906,205.24	2,357,310
6/12/2020	Sell	88,753	$65.08	$5,776,045.24	2,357,310
5/12/2020	Sell	35,865	$57.75	$2,071,203.75	2,272,758
5/8/2020	Sell	4,201	$55.01	$231,097.01	2,272,758
5/5/2020	Sell	8,851	$55.01	$486,893.51	2,277,408
3/4/2020	Sell	40,844	$50.35	$2,056,495.40	2,309,401
2/20/2020	Sell	15,341	$50.21	$770,271.61	2,331,897
2/4/2020	Sell	119,525	$45.18	$5,400,139.50	2,388,082
1/16/2020	Sell	30,317	$41.01	$1,243,300.17	2,298,874
11/26/2019	Sell	279,166	$31.55	$8,807,687.30	2,508,021
4/2/2019	Sell	160,000	$13.72	$2,195,200.00	2,234,610
3/29/2019	Sell	5,755	$14.00	$80,570.00	2,234,610
1/9/2019	Sell	20,170	$12.02	$242,443.40	2,236,130
1/7/2019	Sell	7,275	$12.04	$87,591.00	2,236,130
11/7/2018	Sell	7,211	$12.00	$86,532.00	2,192,205
6/29/2018	Sell	100	$14.10	$1,410.00	2,195,751
5/23/2018	Sell	92,798	$12.84	$1,191,526.32	2,218,932
5/21/2018	Sell	33,938	$12.55	$425,921.90	2,218,932
5/17/2018	Sell	200,000	$11.78	$2,356,000.00	2,284,994
5/15/2018	Sell	100,000	$11.32	$1,132,000.00	2,284,994
5/1/2018	Sell	17,127	$11.00	$188,397.00	2,202,121
4/1/2015	Sell	24,267	$7.50	$182,002.50
3/31/2015	Sell	16,540	$7.55	$124,877.00
3/30/2015	Sell	1,200	$7.51	$9,012.00
3/24/2015	Sell	50,371	$7.84	$394,908.64
3/19/2015	Sell	18,146	$8.34	$151,337.64
3/17/2015	Sell	31,316	$8.55	$267,751.80
5/1/2014	Sell	27,726	$5.59	$154,988.34
4/29/2014	Sell	32,274	$5.38	$173,634.12
3/17/2014	Sell	20,000	$7.25	$145,000.00
7/16/2013	Sell	22,089	$14.39	$317,860.71
5/15/2013	Sell	7,600	$14.04	$106,704.00
4/11/2013	Sell	2,529	$14.02	$35,456.58
3/6/2013	Sell	5,541	$14.01	$77,629.41
2/22/2013	Sell	7,500	$12.06	$90,450.00
10/1/2012	Sell	15,000	$11.53	$172,950.00

Thomas J. Schall Buying and Selling Activity at ChemoCentryx

ChemoCentryx Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Today's Range

Now: $51.99

$51.99

50 Day Range

MA: $51.95

$51.66

$51.99

2 Week Range

Now: $51.99

$14.95

$52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Thomas Schall Biography and Net Worth

What is Thomas J. Schall's net worth?

How old is Thomas J. Schall?

What is Thomas J. Schall's salary?

How do I contact Thomas J. Schall?

Has Thomas J. Schall been buying or selling shares of ChemoCentryx?

Who are ChemoCentryx's active insiders?